U.S. Serial No. 10/031,851 Attorney Docket No.: HMNZ 2 00021

## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

- 1. (Currently Amended) A method of treating diseases of the skin and mucous membranes as well as organs and tissues, except for treatment of retroviral-(HIV)-diseases and disinfection, comprising the administration to the area to be treated of tosylchloramide(s), tosylchloramide salt(s), their derivatives, decomposition products and mixtures thereof for manufacture of medicaments.
- 2. (Previously presented) The method of Claim 1, characterized in that the diseases affect the skin and the mucous membranes.
- 3. (Currently Amended) The method of Claim 2, characterized in that the diseases result or may result in efflorescenses.
- 4. (Currently Amended) The method of Claim 1, characterized in that the diseases and/or efflorescenses may be are caused by microorganisms and/or accompanied by microorganisms.
- 5. (Currently Amended) The method of Claim 1, characterized in that the diseases constitute parasitic diseases, in particular seables, pediculosis or creeping eruption.
- 6. (Currently Amended) The method of Claim 1, characterized in that the diseases affect:
  - a) the eye, in particular the lid, conjunctiva or cornea of the eye;
  - b) the ear, in particular the exterior of the ear;
  - c) the nose, in particular the nasal cavity;
  - d) the lips and mucous membranes of the mouth and/or the tongue;
  - e) the vulva and/or vagina;
  - f) the penis, in particular the glans penis and the prepuce;

U.S. Serial No. 10'031,851 Attorney Docket No.: HMNZ 2 00021

- g) the anus;
- h) the nail, in particular the body of the nail, the wall and fold of the nail as well as the root of the nail;
- i) the hair, in particular the hair follicles and and/or the sebaceous glands; and and/or
- j) the hands and feet, in particular the spaces between the fingers and toes.
- 7. (Previously presented) The method of Claim 1, wherein said tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products are present in an employed base in an amount of approximately 0.1 to 20% by weight.
- 8. (Currently amended) The method of Claim 1, wherein a tosylchloramide salt is employed, in particular chloramine T.
- 9. (Previously presented) The method of Claim 7, wherein the base constitutes a liquid, semi-solid or solid, water-containing or water-free galenic preparation.
- 10. (Previously presented) The method of Claim 9, wherein the base constitutes an ointment, a gel, a cream, a paste, a suppository, such as a vaginal suppository, an adhesive bandage, a tablet, such an effervescent or vaginal tablet, or a capsule, a stick, a pulverized substance, a powder, a solution, an aerosol, a two-compartment system or a suspension, such as a shake mixture/dry suspension.
- 11. (Previously presented) The method of Claim 9, wherein the base constitutes a dosed aerosol or a dosed solution.
- 12. (Previously presented) The method of Claim 9, wherein the base constitutes a bath water additive.

U.S. Serial No. 10/031,851 Attorney Docket No.: HMNZ 2 00021

13. (Previously presented) The method of Claim 9, wherein the salve is an O/W- or a W/O-emulsion ointment.

- 14. (Currently amended) The method of Claim 7, characterized in that wherein the base is a cortisone-containing preparation, containing the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products in an amount of approximately 0.1 to 20% by weight.
- 15. (Previously presented) The method of Claim 9, wherein the base is a gel comprising the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products in an amount of approximately 0.1 to 5% by weight.
- 16. (Previously presented) The method of Claim 9, wherein the bath water additive is employed in form of pulverized substance or bath salt tablet or effervescent tablet, which is applied in water in a concentration of approximately 0.1 to 1% by weight.
- 17. (Previously presented) The method of Claim 1, wherein the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products are present in an employed base in an amount of approximately 5 to 15% by weight.
- 18. (Previously presented) The method of Claim 1, wherein the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products are present in an employed base in an amount of approximately 8 to 12% by weight.
- 19. (Previously presented) The method of Claim 9, wherein the base is a gel, in which are present the tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or decomposition products in an amount of approximately 0.1 to 2% by weight.
  - 20. (Previously presented) A medicament for treating diseases of the skin

U.S. Serial No. 10/031,851 Attorney Docket No.: HMNZ 2 00021

and mucous membranes as well as organs and tissues, except for treatment of retroviral (HIV) diseases and disinfection, comprised of a base material and a tosylchloramide(s), tosylchloramide salt(s), their derivatives, decomposition products and mixtures thereof.